Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Pharm Biomed Anal ; 184: 113176, 2020 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-32092632

RESUMEN

Anticomplement activity played an important role in anti-inflammatory effects of traditional Chinese herbs. The total flavonoids of Sophora tonkinensis (TFST) were inactive on the complement system but showed obvious anticomplement activity after incubated with human intestinal bacteria in vitro. In order to discover the metabolic activation of TFST by intestinal flora, the constituents of TFST and its metabolites were identified by UPLC-ESI-LTQ/MS. Their anticomplement activities were evaluated through the classical and alternative pathway. As a result, eighteen flavonoids were identified, including seven flavonoid glycosides, five aglycones and six isoprenylated flavonoids. All the glycosides (daidzein-4'-glucoside-rhamnoside, sophorabioside, rutin, isoquercitrin, quercitrin, ononin, trifolirhizin) were metabolized into their corresponding aglycones in different extent by human intestinal bacteria, resulting in the contents of the five aglycones were highly increased in 24 h. However, no changes have occurred on the six isoprenylated flavonoids. Interestingly, three aglycones (quercetin, formononetin and maackiain) had significantly more potent anticomplement activities than their prototype glycosides. The results indicated that the enhancement of TFST anticomplement activity was attributed to the active aglycones, especially formononetin and quercetin, produced by human intestinal bacteria. These aglycones are likely to be among the potential active components of S. tonkinensis for its inhibiting inflammation effects.


Asunto(s)
Bacterias/efectos de los fármacos , Proteínas Inactivadoras de Complemento/metabolismo , Flavonoides/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Extractos Vegetales/farmacología , Sophora/química , Adulto , Bacterias/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Heces/microbiología , Femenino , Humanos , Masculino , Espectrometría de Masas en Tándem/métodos , Adulto Joven
2.
J Immunol ; 172(10): 6382-7, 2004 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-15128829

RESUMEN

PL37 (RAARISLGPRCIKAFTE) is an antisense homology box peptide composed of aa 37-53 of C5a-anaphylatoxin and is considered to be the region essential for C5a function. Using a computer program, we designed the complementary peptides ASGAPAPGPAGPLRPMF (Pep-A) and ASTAPARAGLPRLPKFF (Pep-B). Pep-A bound to PL37 and to C5a with very slow dissociation as determined by analysis using surface plasmon resonance, whereas Pep-B failed to bind at all. C5a was inactivated by concentrations of 7 nM or more of Pep-A, and this concentration of Pep-A inhibited induction of intracellular Ca(2+) influx in neutrophils. Patch clamp electrophysiology experiments also showed the effectiveness of Pep-A in C5aR-expressing neuroblastoma cells. Furthermore, Pep-A administration prevented rats from C5a-mediated rapid lethal shock induced by an Ab to a membrane inhibitor of complement after LPS sensitization.


Asunto(s)
Complemento C5a/antagonistas & inhibidores , Complemento C5a/metabolismo , Proteínas Inactivadoras de Complemento/fisiología , Fragmentos de Péptidos/fisiología , Secuencia de Aminoácidos , Anafilaxia/mortalidad , Anafilaxia/prevención & control , Animales , Antígenos/química , Antígenos/metabolismo , Antígenos/fisiología , Elementos sin Sentido (Genética)/síntesis química , Elementos sin Sentido (Genética)/metabolismo , Elementos sin Sentido (Genética)/fisiología , Calcio/metabolismo , Línea Celular Tumoral , Separación Celular , Complemento C5a/fisiología , Proteínas Inactivadoras de Complemento/síntesis química , Proteínas Inactivadoras de Complemento/metabolismo , Modelos Animales de Enfermedad , Humanos , Líquido Intracelular/metabolismo , Masculino , Datos de Secuencia Molecular , Neutrófilos/inmunología , Neutrófilos/metabolismo , Técnicas de Placa-Clamp , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/metabolismo , Unión Proteica/inmunología , Ratas , Ratas Wistar
3.
Biochemistry (Mosc) ; 66(7): 703-14, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11563948

RESUMEN

The medicinal leech Hirudo medicinalis produces various types of proteinase inhibitors: bdellins (inhibitors of trypsin, plasmin, and acrosin), hirustasin (inhibitor of tissue kallikrein, trypsin, alpha-chymotrypsin, and granulocyte cathepsin G), tryptase inhibitor, eglins (inhibitors of alpha-chymotrypsin, subtilisin, and chymasin and the granulocyte proteinases elastase and cathepsin G), inhibitor of factor Xa, hirudin (thrombin inhibitor), inhibitor of carboxypeptidase, and inhibitor of complement component C1s. This review summarizes data on their primary and tertiary structures, action mechanisms, and biological activities.


Asunto(s)
Hormonas de Invertebrados/aislamiento & purificación , Sanguijuelas/química , Compuestos Orgánicos , Inhibidores de Proteasas/aislamiento & purificación , Animales , Antitrombina III/aislamiento & purificación , Antitrombina III/metabolismo , Antitrombina III/farmacología , Carboxipeptidasas/antagonistas & inhibidores , Carboxipeptidasas/metabolismo , Carboxipeptidasas A , Proteínas Inactivadoras de Complemento/aislamiento & purificación , Proteínas Inactivadoras de Complemento/metabolismo , Proteínas Inactivadoras de Complemento/farmacología , Hirudinas/química , Hirudinas/farmacología , Humanos , Hormonas de Invertebrados/metabolismo , Hormonas de Invertebrados/farmacología , Sanguijuelas/metabolismo , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Proteínas , Serina Endopeptidasas/efectos de los fármacos , Serina Endopeptidasas/metabolismo , Serpinas/aislamiento & purificación , Serpinas/metabolismo , Serpinas/farmacología , Triptasas
4.
J Immunol ; 166(10): 6341-8, 2001 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-11342658

RESUMEN

The anaphylatoxin C3a is a potent chemotactic peptide and inflammatory mediator released during complement activation which binds to and activates a G-protein-coupled receptor. Molecular cloning of the C3aR has facilitated studies to identify nonpeptide antagonists of the C3aR. A chemical lead that selectively inhibited the C3aR in a high throughput screen was identified and chemically optimized. The resulting antagonist, N(2)-[(2,2-diphenylethoxy)acetyl]-L-arginine (SB 290157), functioned as a competitive antagonist of (125)I-C3a radioligand binding to rat basophilic leukemia (RBL)-2H3 cells expressing the human C3aR (RBL-C3aR), with an IC(50) of 200 nM. SB 290157 was a functional antagonist, blocking C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca(2+) mobilization in RBL-C3aR cells and human neutrophils with IC(50)s of 27.7 and 28 nM, respectively. SB 290157 was selective for the C3aR in that it did not antagonize the C5aR or six other chemotactic G protein-coupled receptors. Functional antagonism was not solely limited to the human C3aR; SB 290157 also inhibited C3a-induced Ca(2+) mobilization of RBL-2H3 cells expressing the mouse and guinea pig C3aRS: It potently inhibited C3a-mediated ATP release from guinea pig platelets and inhibited C3a-induced potentiation of the contractile response to field stimulation of perfused rat caudal artery. Furthermore, in animal models, SB 290157, inhibited neutrophil recruitment in a guinea pig LPS-induced airway neutrophilia model and decreased paw edema in a rat adjuvant-induced arthritis model. This selective antagonist may be useful to define the physiological and pathophysiological roles of the C3aR.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Arginina/farmacología , Compuestos de Bencidrilo/farmacología , Complemento C3a/metabolismo , Proteínas Inactivadoras de Complemento/farmacología , Proteínas de la Membrana , Receptores de Complemento/antagonistas & inhibidores , Animales , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/farmacocinética , Arginina/análogos & derivados , Arginina/metabolismo , Arginina/farmacocinética , Artritis Experimental/inmunología , Artritis Experimental/patología , Compuestos de Bencidrilo/metabolismo , Compuestos de Bencidrilo/farmacocinética , Unión Competitiva , Línea Celular , Proteínas Inactivadoras de Complemento/metabolismo , Proteínas Inactivadoras de Complemento/farmacocinética , Modelos Animales de Enfermedad , Edema/patología , Edema/prevención & control , Cobayas , Miembro Posterior , Humanos , Inyecciones Intraperitoneales , Leucocitosis/inmunología , Leucocitosis/patología , Masculino , Ratones , Contracción Muscular/efectos de los fármacos , Infiltración Neutrófila/efectos de los fármacos , Ratas , Ratas Endogámicas Lew , Ratas Sprague-Dawley , Receptores de Complemento/metabolismo , Células Tumorales Cultivadas
5.
Exp Nephrol ; 7(3): 217-28, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10352362

RESUMEN

Preformed xenoreactive natural antibodies (XNA) and complement mediate hyperacute xenograft rejection (HXR) in pig-to-human discordant xenotransplantation. In a pig kidney-human blood xenoperfusion model, we investigated whether XNA depletion and/or human complement inactivation preserved early pig kidney function. Pig kidneys were perfused for 180 min with pig blood (AUTO group, n = 8), human blood (HETER group, n = 6), complement-inactivated human blood (COMi group, n = 5), XNA-depleted human blood (ABd group, n = 5) or complement-inactivated and XNA-depleted human blood (ABd&COMi group, n = 5). HETER kidneys were rejected after 15-30 min and showed vascular microthrombi and interstitial hemorrhages. XNA depletion and/or complement inactivation prevented HXR. The glomerular filtration rate in ABd, COMi and ABd&COMi groups was significantly lower than in the AUTO group. Also, beyond 60 min, the COMi group showed a significantly lower glomerular filtration rate than that observed in ABd and ABd&COMi groups. Kidneys from ABd, COMi and ABd&COMi groups displayed endothelial cell edema, as well as higher soluble P-selectin levels and a higher renal myeloperoxidase content than the AUTO group kidneys. COMi and ABd&COMi groups had a significantly lower renal myeloperoxidase level than the HETER group. Also, in contrast to HETER and ABd groups, these complement-inactivated groups failed to show a positive correlation between P-selectin and renal myeloperoxidase. We also investigated platelet-activating factor (PAF) as possible mediator for these functional and pathologic changes. We found that blood PAF levels were similar in HETER, ABd, COMi and ABd&COMi groups and significantly higher than in the AUTO group. Also, when PAF was added to porcine endothelial cell monolayers, morphological changes due to cytoskeleton contraction were observed, and these changes were prevented by preincubation with a PAF receptor antagonist. In conclusion, although depletion of XNA and/or complement inactivation prevent HXR, the pig kidney function is not preserved at the level of the autologous combination. The PAF overproduction observed in the xenogenic combination, which is independent of the presence of XNA and complement, may be, at least in part, responsible for early endothelial cell morphological changes still present when HXR is prevented.


Asunto(s)
Anticuerpos Heterófilos/aislamiento & purificación , Proteínas Inactivadoras de Complemento/metabolismo , Trasplante de Riñón/inmunología , Trasplante de Riñón/fisiología , Riñón/inmunología , Riñón/fisiología , Animales , Anticuerpos Heterófilos/sangre , Transfusión Sanguínea , Transfusión de Sangre Autóloga , Endotelio Vascular/inmunología , Endotelio Vascular/patología , Tasa de Filtración Glomerular , Rechazo de Injerto/inmunología , Rechazo de Injerto/fisiopatología , Rechazo de Injerto/prevención & control , Humanos , Riñón/patología , Trasplante de Riñón/patología , Masculino , Selectina-P/metabolismo , Perfusión , Peroxidasa/metabolismo , Factor de Activación Plaquetaria/metabolismo , Flujo Plasmático Renal , Porcinos , Trasplante Heterólogo , Resistencia Vascular
6.
Rheumatol Int ; 12(5): 201-5, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1283924

RESUMEN

The decay-accelerating factor (DAF) is a complement regulatory cell surface protein that protects cells from complement-mediated lysis. We analysed synovial tissue biopsies from patients with chronic arthritides for the presence of DAF using immunohistochemistry. DAF was expressed in the synovial lining cell layer both in rheumatoid arthritis (RA) and in osteoarthritis (OA). DAF was also on vascular endothelial cells of synovial tissue. A significant correlation was found between the expression of DAF and of HLA-DR in the lining layer, suggesting that DAF may be induced during a local inflammatory response. In addition, C5b-9 terminal complement complexes were found in several DAF-positive cases, suggesting that complement activation might, in itself, induce DAF expression. We propose that the occurrence of DAF may represent a physiological mechanism for local complement regulation in synovial tissue.


Asunto(s)
Antígenos CD/metabolismo , Artritis/metabolismo , Glicoproteínas de Membrana/metabolismo , Membrana Sinovial/metabolismo , Adulto , Anciano , Artritis/patología , Antígenos CD55 , Proteínas Inactivadoras de Complemento/metabolismo , Ensayo de Inmunoadsorción Enzimática , Espacio Extracelular/metabolismo , Femenino , Humanos , Inmunohistoquímica/métodos , Masculino , Persona de Mediana Edad , Coloración y Etiquetado , Membrana Sinovial/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA